Dashboard
Company has a low Debt to Equity ratio (avg) at 0 times
Poor long term growth as Net Sales has grown by an annual rate of -1.11% and Operating profit at -17.05% over the last 5 years
Flat results in Sep 25
With ROE of 6.6, it has a Very Expensive valuation with a 1.4 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0.04% of the company
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,384 Cr (Small Cap)
21.00
40
0.96%
-0.01
6.62%
1.37
Total Returns (Price + Dividend) 
Latest dividend: 4 per share ex-dividend date: Feb-18-2025
Risk Adjusted Returns v/s 
Returns Beta
News

IOL Chemicals & Pharmaceuticals: Technical Momentum Shifts Amid Mixed Market Signals
IOL Chemicals & Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition from a mildly bullish trend to a sideways movement, underscoring the nuanced position of the stock within the Pharmaceuticals & Biotechnology sector.
Read More
IOL Chemicals & Pharmaceuticals: Analytical Perspective Shift Reflects Mixed Financial and Technical Signals
IOL Chemicals & Pharmaceuticals has experienced a revision in its market assessment, reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This shift comes amid a backdrop of flat quarterly financial performance, subdued long-term sales growth, and evolving technical signals, prompting a reassessment of the company’s standing within the Pharmaceuticals & Biotechnology sector.
Read More
IOL Chemicals & Pharmaceuticals Technical Momentum Shifts Amid Mixed Indicators
IOL Chemicals & Pharmaceuticals has exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This development comes amid a complex interplay of technical indicators, including mixed signals from MACD, RSI, moving averages, and other momentum measures, reflecting a nuanced market assessment for the pharmaceutical sector player.
Read More Announcements 
IOL Chemicals and Pharmaceuticals Limited - Updates
27-Nov-2019 | Source : NSEIOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding 'Copy of Notice published in newspapers regarding loss of Share Certificates'.
IOL Chemicals and Pharmaceuticals Limited - Updates
18-Nov-2019 | Source : NSEIOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding 'Submission of newspaper cutting of audited financial results for the quarter and half year ended 30 September 2019'.
IOL Chemicals and Pharmaceuticals Limited - Change in Company Secretary / Compliance Officer
15-Nov-2019 | Source : NSEIOL Chemicals and Pharmaceuticals Limited has informed the Exchange about The Board of Directors in its meeting held on 14.11.2019 has approved the appointment of Mr Abhay Raj Singh as Company Secretary and Compliance Officer of the Company in place of Mr Krishan Singla, Vice President & Company Secretary, who is getting superannuated on 14 November 2019
Corporate Actions 
No Upcoming Board Meetings
IOL Chemicals & Pharmaceuticals Ltd has declared 40% dividend, ex-date: 18 Feb 25
IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.02%)
Held by 60 FIIs (2.25%)
Maya Devi Polycot Limited (21.54%)
Vasudeva Commercials Limited (7.94%)
29.97%
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 2.87% vs 4.53% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -11.67% vs 7.99% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024
Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is -4.75% vs -0.06% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -34.79% vs 43.64% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024
YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024






